Outlook Therapeutics, Inc.
OTLK Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$0.52
KIRA · Stoqly’s AI analyst, in plain words
- Outlook Therapeutics, Inc. had $1.4M of revenue in fiscal 2025.
- Its operating margin was −4,744.4%, down 7,015.6 pts: of every 100 in sales, about −4,744 is left after running the business.
- Outlook Therapeutics, Inc. lost $62.4M in fiscal 2025.
Market cap
$71.0M
P/E
—
Revenue
$1.4M
Net income
−$62.4M
Free cash flow
—
Operating margin
−4,744.4%
Outlook Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−4,416.3%
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Outlook Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 10-K · Dec 19, 2025
- Legal name
- Outlook Therapeutics, Inc.
- CIK
- 0001649989
Outlook Therapeutics, Inc. · OTLK
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | −$0.9M | −$1.5M | −$1.6M | −$3.2M | $1.4M |
| Net interest income | −$0.9M | −$1.5M | −$1.6M | −$3.2M | −$0.3M |
| Gross margin | — | — | — | — | 4.0% |
| Operating margin | 5,525.8% | 4,240.1% | 3,406.2% | 2,271.2% | −4,744.4% |
| Net income | −$53.2M | −$66.1M | −$59.0M | −$75.4M | −$62.4M |
| Net margin | 5,679.2% | 4,440.5% | 3,781.7% | 2,387.3% | −4,416.3% |
| Diluted EPS | −$0.35 | −$0.31 | −$4.72 | −$4.06 | −$1.79 |
| Cash | |||||
| Cash from operations | −$54.3M | −$56.7M | −$43.0M | −$68.8M | −$51.8M |
| Share count change | 110.4% | 38.9% | −94.1% | 48.3% | 87.6% |
| Debt and strength | |||||
| Cash and short-term investments | $14.5M | $17.4M | $23.4M | $14.9M | $8.1M |
| Shareholders' equity | $4.6M | $8.7M | −$14.4M | −$73.1M | −$32.2M |
| Current ratio | 3.2x | 1.4x | 0.7x | 0.6x | 0.4x |
| Interest coverage | — | — | −21.0x | −22.7x | — |
| Returns and quality | |||||
| Return on equity | −1,430.3% | −990.0% | — | — | — |
| Return on tangible equity | −1,153.9% | −756.0% | — | — | — |
| Piotroski F-score | 2 | 2 | 4 | 1 | 2 |
| Altman Z'' | −59.7 | −59.3 | −61.8 | −82.4 | −141.2 |
Insiders bought, 12 months
$7.9M
6 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Outlook Therapeutics, Inc. · OTLK
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.52 a share, the company is worth $71.0M.
Source: SEC EDGAR XBRL filings (CIK 0001649989). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.